The former refers to the ability of cancer cells to generate novel genetic modifications or mutations that provide resistance to specific therapies, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or proto-oncogene tyrosine protein kinase-1 (ROS1) mutations. Here, ROS1 is linked to cancer.